---
figid: PMC7912095__diagnostics-11-00196-g002
figlink: pmc/articles/PMC7912095/figure/diagnostics-11-00196-f002/
number: Figure 2
caption: Loss of LKB1 drives the tumor immune escape. The loss of LKB1, the second
  most commonly altered tumor suppressor in NSCLC, promotes the production of SAM,
  a substrate for the DNA and histone methyltransferases DNMT1, EZH2 and other epigenetic
  silencing enzymes. This downregulates the expression of STING, impairing dsDNA sensing,
  and thereby the expression of immune checkpoint regulating proteins like PD-L1 and
  T cell chemokines. Therefore, the LKB1-deficient tumors are characterized by a so-called
  “cold” immunosuppressive tumor microenvironment (blue), which shows the striking
  infiltration of immunosuppressive cells (TAN; tumor-associated neutrophil; Treg,
  T lymphocyte regulator, blue) and the exclusion of inflamed immune cells (CD8 T
  cells, NK, CD4 T cells and M1; Macrophage type 1, red). Epigenetic therapies that
  reactivate LKB1 or the STING pathway may boost an anticancer immune response in
  LKB1-deficient cancers with the resistance to immune-checkpoint blockade (ICI, immune
  checkpoint inhibitor).
pmcid: PMC7912095
papertitle: The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas.
reftext: Baharia Mograbi, et al. Diagnostics (Basel). 2021 Feb;11(2):196.
pmc_ranked_result_index: '93505'
pathway_score: 0.8308248
filename: diagnostics-11-00196-g002.jpg
figtitle: Loss of LKB1 drives the tumor immune escape
year: '2021'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7912095__diagnostics-11-00196-g002.html
  '@type': Dataset
  description: Loss of LKB1 drives the tumor immune escape. The loss of LKB1, the
    second most commonly altered tumor suppressor in NSCLC, promotes the production
    of SAM, a substrate for the DNA and histone methyltransferases DNMT1, EZH2 and
    other epigenetic silencing enzymes. This downregulates the expression of STING,
    impairing dsDNA sensing, and thereby the expression of immune checkpoint regulating
    proteins like PD-L1 and T cell chemokines. Therefore, the LKB1-deficient tumors
    are characterized by a so-called “cold” immunosuppressive tumor microenvironment
    (blue), which shows the striking infiltration of immunosuppressive cells (TAN;
    tumor-associated neutrophil; Treg, T lymphocyte regulator, blue) and the exclusion
    of inflamed immune cells (CD8 T cells, NK, CD4 T cells and M1; Macrophage type
    1, red). Epigenetic therapies that reactivate LKB1 or the STING pathway may boost
    an anticancer immune response in LKB1-deficient cancers with the resistance to
    immune-checkpoint blockade (ICI, immune checkpoint inhibitor).
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - KRAS
  - STK11
  - PRKAG2
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG3
  - EZH2
  - DNMT1
  - TMEM173
  - CD274
  - CD8A
  - CD8B
  - CD4
  - PPBP
  - CCL5
  - CXCL12
  - Serine-glycine
  - carbon
  - "STING \x1F Me \x1F Me \x1F Me \x1F"
  - ICI
  - IMMUNO
  - IMMUNOTHERAPY
  - NSCLC
  - LKB1-deficient tumour
genes:
- word: KRAS
  symbol: KRAS
  source: hgnc_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: LKB1
  symbol: LKB1
  source: hgnc_alias_symbol
  hgnc_symbol: STK11
  entrez: '6794'
- word: LKB1
  symbol: LKB1
  source: hgnc_alias_symbol
  hgnc_symbol: STK11
  entrez: '6794'
- word: LKB1
  symbol: LKB1
  source: hgnc_alias_symbol
  hgnc_symbol: STK11
  entrez: '6794'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG2
  entrez: '51422'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA1
  entrez: '5562'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAA2
  entrez: '5563'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB1
  entrez: '5564'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAB2
  entrez: '5565'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG1
  entrez: '5571'
- word: AMPK
  symbol: AMPK
  source: bioentities_symbol
  hgnc_symbol: PRKAG3
  entrez: '53632'
- word: EZH2
  symbol: EZH2
  source: hgnc_symbol
  hgnc_symbol: EZH2
  entrez: '2146'
- word: DNMT1
  symbol: DNMT1
  source: hgnc_symbol
  hgnc_symbol: DNMT1
  entrez: '1786'
- word: STING
  symbol: STING
  source: hgnc_alias_symbol
  hgnc_symbol: TMEM173
  entrez: '340061'
- word: PD-L1
  symbol: PD-L1
  source: hgnc_alias_symbol
  hgnc_symbol: CD274
  entrez: '29126'
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8A
  entrez: '925'
- word: CD8
  symbol: CD8
  source: bioentities_symbol
  hgnc_symbol: CD8B
  entrez: '926'
- word: CD4
  symbol: CD4
  source: hgnc_symbol
  hgnc_symbol: CD4
  entrez: '920'
- word: CXCL7
  symbol: CXCL7
  source: hgnc_alias_symbol
  hgnc_symbol: PPBP
  entrez: '5473'
- word: ´CCL5
  symbol: CCL5
  source: hgnc_symbol
  hgnc_symbol: CCL5
  entrez: '6352'
- word: CXCL12
  symbol: CXCL12
  source: hgnc_symbol
  hgnc_symbol: CXCL12
  entrez: '6387'
chemicals:
- word: Serine-glycine
  source: MESH
  identifier: D005998
- word: carbon
  source: MESH
  identifier: D002244
- word: "STING \x1F Me \x1F Me \x1F Me \x1F"
  source: MESH
  identifier: C526611
- word: ICI
  source: MESH
  identifier: C481040
- word: IMMUNO
  source: MESH
  identifier: C476547
- word: IMMUNOTHERAPY
  source: ''
  identifier: ''
diseases:
- word: NSCLC
  source: MESH
  identifier: D002289
- word: LKB1-deficient tumour
  source: MESH
  identifier: D009369
---
